Company Filing History:
1 out of 832,912 Years Active: 2004
Title: Innovator Spotlight: Doug Barnum and His Contributions to Medical Chemistry
Introduction: Doug Barnum, based in San Francisco, CA, is a distinguished inventor known for his innovative work in medicinal chemistry. His contributions focus on the development of chemokine receptor antagonists, which are critical in the treatment of various diseases. With one patent to his name, Barnum is making strides in the field of therapeutic drug development.
Latest Patents: Doug Barnum holds a patent titled "Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists." This patent details cyclic diamines described by a specific formula and their pharmacologically acceptable acid addition salts. The invention primarily aims to inhibit the action of chemokines such as MIP-1a and MCP-1 on target cells. These compounds have significant medical applications, particularly in treating and preventing conditions like atherosclerosis and rheumatoid arthritis, where infiltration of blood monocytes and lymphocytes into tissue is problematic.
Career Highlights: Throughout his career, Doug Barnum has focused on innovations that directly impact patient care and treatment methodologies. His dedication to research and development has led to significant breakthroughs in understanding and combating diseases characterized by inflammatory processes.
Collaborations: In his innovative journey, Doug has collaborated with notable colleagues, including Tatsuki Shiota and Shinsuke Yamagami. Together, they have contributed to advancing research in therapeutic applications and developing new strategies for drug discovery.
Conclusion: Doug Barnum embodies the spirit of innovation in the realm of medical chemistry. His patent not only showcases his technical expertise but also highlights the potential for new therapeutic avenues for diseases that currently pose significant challenges in medical science. Through ongoing research and collaboration, Doug continues to be a valuable contributor to the field, paving the way for future advancements in the treatment of critical health concerns.